Note*: This report requires 7-10 business days to complete.
DelveInsight’s Benign prostatic hyperplasia (BPH) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Benign prostatic hyperplasia (BPH) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Benign prostatic hyperplasia (BPH) till 2023.
Key Coverage and Benefits
• The report will help in developing business strategies by understanding the trends shaping and driving the global Benign prostatic hyperplasia (BPH) market.
• Identifying patient populations in the global “Benign prostatic hyperplasia (BPH)market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Benign prostatic hyperplasia (BPH) therapeutics in each of the markets covered.
• To understand the future market competition in the global Benign prostatic hyperplasia (BPH) therapeutics market and Insightful review of the key market drivers and barriers.
Scope
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides Benign prostatic hyperplasia (BPH) for United States, EU5 and Japan from 2013 and forecasted Market to 2023.
'
Table of Contents
• Benign prostatic hyperplasia (BPH) overview
• Pathophysiology
• Symptoms of disease
• Etiology of disease
• Diagnosis of disease
• Treatment of disease
• Overview of Marketed drugs
• Drug Description
• Mechanism of Action
• Pharmacokinetics Properties
• Marketed Details
• Patent Information
• Patent Exclusivity Expiry Assessment United States (US)
• Patents Details
• Historical and Forecasted sales of marketed molecules in the Global Benign prostatic hyperplasia (BPH) Market
• Global Epidemiology of Benign prostatic hyperplasia (BPH) Forecasted to 2023
• Global Market (2013-2015)
• Global Forecasted Market (2016-2023)
• Global Market by Geography
• Market of US (2013-2015)
• Forecasted Market of US (2016-2023)
• Market of Europe
• Market of Germany (2013-2015)
• Forecasted Market of Germany (2016-2023)
• Market of United Kingdom (2013-2015)
• Forecasted Market of United Kingdom (2016-2023)
• Market of France (2013-2015)
• Forecasted Market of France (2016-2023)
• Market of Italy (2013-2015)
• Forecasted Market of Italy (2016-2023)
• Market of Spain (2013-2015)
• Forecasted Market of Spain (2016-2023)
• Market of Japan (2013-2015)
• Forecasted Market of Japan (2016-2023)
• Market of ROW (2013-2015)
• Forecasted Market of ROW (2016-2023)
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight
List of Tables
• Table 1: Drug Description
• Table 2: Drug, Marketed Details United States (US)
• Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
• Table 4: Drug, Patent Details for US
• Table 5: Benign prostatic hyperplasia (BPH) Drug Sales (USD Millions)-2023
• Table 6: Global Epidemiology of Benign prostatic hyperplasia (BPH) (2013-2023)
• Table 7: Benign prostatic hyperplasia (BPH) Global Market (USD Millions), (2013-2015)
• Table 8: Benign prostatic hyperplasia (BPH) Global Market (USD Millions), (2016-2023)
• Table 9: Benign prostatic hyperplasia (BPH) US Market (USD Millions), (2013-2015)
• Table 10: Benign prostatic hyperplasia (BPH) US Market (USD Millions), (2016-2023)
• Table 11: Benign prostatic hyperplasia (BPH) Germany Market (USD Millions), (2013-2015)
• Table 12: Benign prostatic hyperplasia (BPH) Germany Market (USD Millions), (2016-2023)
• Table 13: Benign prostatic hyperplasia (BPH) United Kingdom Market (USD Millions), (2013-2015)
• Table 14: Benign prostatic hyperplasia (BPH) United Kingdom Market (USD Millions), (2016-2023)
• Table 15: Benign prostatic hyperplasia (BPH) France Market (USD Millions), (2013-2015)
• Table 16: Benign prostatic hyperplasia (BPH) France Market (USD Millions), (2016-2023)
• Table 17: Benign prostatic hyperplasia (BPH) Italy Market (USD Millions), (2013-2015)
• Table 18: Benign prostatic hyperplasia (BPH) Italy Market (USD Millions), (2016-2023)
• Table 19: Benign prostatic hyperplasia (BPH) Spain Market (USD Millions), (2013-2015)
• Table 20: Benign prostatic hyperplasia (BPH) Spain Market (USD Millions), (2016-2023)
• Table 21: Benign prostatic hyperplasia (BPH) Japan Market (USD Millions), (2013-2015)
• Table 22: Benign prostatic hyperplasia (BPH) Japan Market (USD Millions), (2016-2023)
• Table 23: Benign prostatic hyperplasia (BPH) ROW Market (USD Millions), (2013-2015)
• Table 24: Benign prostatic hyperplasia (BPH) ROW Market (USD Millions), (2016-2023)
List of Figures
• Figure 1: Benign prostatic hyperplasia (BPH) Drug Sales (USD Millions)-2023
• Figure 2: Global Epidemiology of Benign prostatic hyperplasia (BPH) (2013-2023)
• Figure 3: Benign prostatic hyperplasia (BPH) Global Market (USD Millions), (2013-2015)
• Figure 4: Benign prostatic hyperplasia (BPH) Global Market (USD Millions), (2016-2023)
• Figure 5: Benign prostatic hyperplasia (BPH) US Market (USD Millions), (2013-2015)
• Figure 6: Benign prostatic hyperplasia (BPH) US Market (USD Millions), (2016-2023)
• Figure 7: Benign prostatic hyperplasia (BPH) Germany Market (USD Millions), (2013-2015)
• Figure 8: Benign prostatic hyperplasia (BPH) Germany Market (USD Millions), (2016-2023)
• Figure 9: Benign prostatic hyperplasia (BPH) United Kingdom Market (USD Millions), (2013-2015)
• Figure 10: Benign prostatic hyperplasia (BPH) United Kingdom Market (USD Millions), (2016-2023)
• Figure 11: Benign prostatic hyperplasia (BPH) France Market (USD Millions), (2013-2015)
• Figure 12: Benign prostatic hyperplasia (BPH) France Market (USD Millions), (2016-2023)
• Figure 13: Benign prostatic hyperplasia (BPH) Italy Market (USD Millions), (2013-2015)
• Figure 14: Benign prostatic hyperplasia (BPH) Italy Market (USD Millions), (2016-2023)
• Figure 15: Benign prostatic hyperplasia (BPH) Spain Market (USD Millions), (2013-2015)
• Figure 16: Benign prostatic hyperplasia (BPH) Spain Market (USD Millions), (2016-2023)
• Figure 17: Benign prostatic hyperplasia (BPH) Japan Market (USD Millions), (2013-2015)
• Figure 18: Benign prostatic hyperplasia (BPH) Japan Market (USD Millions), (2015-2023)
• Figure 19: Benign prostatic hyperplasia (BPH) ROW Market (USD Millions), (2013-2015)
• Figure 20: Benign prostatic hyperplasia (BPH) ROW Market (USD Millions), (2016-2023)
• Market (7MM)
• Market forecasting
• Sales forecasting
• Market segments
• Pipeline products and technologies
• Competitive landscape
• SWOT analysis
